Norwegian startup ClexBio is bioengineering human veins to implant inside a patient’s body. Together with CSEM, a Swiss R&D centre, the company has built a prototype bioreactor to grow the veins. Pre-clinical tests in animal models are already underway. Based on the early results, the team is confident that the implants don’t trigger an immune response in patients. Instead, they turn into functional tissue that integrates with the body. If further tests prove successful, the implants could treat severe chronic venous insufficiency, a painful condition caused when veins have problems moving blood to the heart. But veins are just the start…
This story continues at The Next Web
